AstraZeneca has halted its £200m Cambridge research site project, stalling its entire £650m UK investment plan.
The Cambridge expansion was expected to create 1,000 jobs, following January’s cancellation of a £450m Speke vaccine facility.
A spokesperson confirmed the pause, offering no further details.
Meanwhile, AstraZeneca pledged $50bn investment in the US by 2030, funding new drug manufacturing and research facilities.
The pause follows a week of setbacks for UK pharma, including Merck scrapping a £1bn London research centre and cutting 125 jobs.
Eli Lilly also put a £279m London lab project on hold, while Sanofi warned of stalled inward investment without Treasury reforms.
Industry leaders argue UK drug spending must rise to match global standards, pressing the government for competitive life sciences policies.
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment